Successful treatment of high risk/refractory leukemia by tumor-ablative individualized conditioning allogeneic hematopoietic stem cell transplantation

To explore the efficacy of tumor-ablative individualized allogeneic hematopoietic stem cell transplantation for the treatment of patients with high risk/refractory leukemia. Fivety-seven patients with high risk/refractory leukemia were enrolled. Tumor-ablative individualized conditioning regimens in...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá xuèyèxué zázhì Vol. 31; no. 8; p. 505
Main Authors Wang, Jing-Bo, DA, Wan-Ming, Zhang, Jian-Ping, Luo, Rong-Mu, Sun, Yuan, Wei, Zhi-Jie, Zhang, Wei-Jie, Zhao, Yan-Li, Wu, Tong, Tong, Chun-Rong, Lu, Dao-Pei
Format Journal Article
LanguageChinese
Published China 01.08.2010
Subjects
Cytarabine
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Leukemia
Transplantation Conditioning
Online AccessGet more information

Cover

More Information
Summary:To explore the efficacy of tumor-ablative individualized allogeneic hematopoietic stem cell transplantation for the treatment of patients with high risk/refractory leukemia. Fivety-seven patients with high risk/refractory leukemia were enrolled. Tumor-ablative individualized conditioning regimens included HDAra-C + Bu/Cy, Ara-C + Bu/Fludarabine, G-CSF primed HDAra-C + Bu/Cy, and FLAG followed by reduced-intensified BuCy. Overall survival (OS), disease free survival (DFS), graft versus host disease, infection and relapse post grafting were analyzed. Fifty-six patients attained durable engraftment. The median follow-up duration was 17.5 (2 - 34) months. The 18 months probabilities of OS and DFS were (74.7 ± 6.1)% and (62.4 ± 6.7)%, respectively. In addition, the 18 months probabilities of OS and DFS in patients who attained complete remission (CR) before transplantation were (74.2 ± 7.1)% and (58.8 ± 8.1)%, respectively, while in those not attained CR were (77.0 ± 11.8)% and (72.7 ± 11.7)%, respectively. Twenty
ISSN:0253-2727